IOVANCE BIOTHERAPEUTICS INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
IOVA$8.08-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands)
| | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | |
| · · · Years Ended December 31, | ||||||||||
| · · · 2023 · 2022 · 2021 | ||||||||||
| Net Loss | | | $(444,037) | | $(395,893) | | $(342,252) | |||
| Other comprehensive loss: | | | | | ||||||
| Unrealized gain/(loss) on investments | | | | 940 | | | (301) | | | (620) |
| Foreign currency translation adjustment | | | 2,488 | | — | | — | |||
| Comprehensive Loss | | | $(440,609) | | $(396,194) | | $(342,872) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.